Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

Neurology. 2009 Feb 24;72(8):772-3; author reply 773-4. doi: 10.1212/01.wnl.0000339387.03225.0a.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Brain Neoplasms / drug therapy
  • Glioma / drug therapy*
  • Humans
  • Neoplasm Recurrence, Local / drug therapy
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab